Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer

• DOI: 10.1111/cas.14732
• Publication Date: 2020-11-13T13:53:27Z
• Authors: Yan Ma; Xiao Wang; Cuipeng Qiu; Jiejie Qin; Keyan Wang; Guiying Sun; Di Jiang; Jitian Li; Lin Wang; Jianxiang Shi; Peng Wang; Hua Ye; Liping Dai; Bing‐Hua Jiang; Jianying Zhang
• Keywords: Protein microarray; GNAS complex locus

Abstract The aim of this study was to develop a noninvasive serological diagnostic approach in identifying and evaluating panel candidate autoantibodies tumor‐associated antigens (TAAs) based on protein microarray technology for early detection ovarian cancer (OC). Protein 154 proteins encoded by 138 driver genes used screen anti‐TAA discovery cohort containing 17 OC 27 normal controls (NC). Indirect enzyme‐linked immunosorbent assay (ELISA) detect the content sera from 140 subjects training cohort. Differential were further validated validation with 328 subjects. Subsequently, 112 patients benign diseases 104 NC together recruited identify specificity representative among diseases. Five TAAs (GNAS, NPM1, FUBP1, p53, KRAS) screened out phase, which four them presented higher levels than ( P < .05) cohort, consistent result subsequent An optimized three NPM1) identified have relatively high sensitivity (51.2%), (86.0%), accuracy (68.6%), respectively. This can 51% CA125 negative. supports our assumption that be considered as potential biomarkers OC; especially could good tool immunodiagnosis OC.